IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been given a consensus rating of “Moderate Buy” by the ten brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $783.3333.

Several equities research analysts have commented on IDXX shares. Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. BTIG Research reduced their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. UBS Group cut their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Finally, Piper Sandler reduced their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th.

IDEXX Laboratories Price Performance

IDXX stock opened at $577.12 on Thursday. The firm has a 50 day moving average price of $651.11 and a 200-day moving average price of $665.40. IDEXX Laboratories has a 52-week low of $356.14 and a 52-week high of $769.98. The firm has a market capitalization of $45.89 billion, a price-to-earnings ratio of 44.16, a PEG ratio of 3.56 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the firm earned $2.53 earnings per share. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts forecast that IDEXX Laboratories will post 11.93 EPS for the current fiscal year.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 1,464 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 11,345 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 45,957 shares of company stock valued at $29,862,109. Company insiders own 0.98% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. World Investment Advisors boosted its position in shares of IDEXX Laboratories by 126.2% during the fourth quarter. World Investment Advisors now owns 1,902 shares of the company’s stock valued at $1,287,000 after buying an additional 1,061 shares during the last quarter. Union Savings Bank purchased a new position in IDEXX Laboratories in the 4th quarter worth about $2,368,000. SHP Wealth Management purchased a new position in IDEXX Laboratories in the 4th quarter worth about $26,000. Reflection Asset Management bought a new position in IDEXX Laboratories during the 4th quarter valued at about $53,000. Finally, BDFS Capital LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at about $671,000. 87.84% of the stock is owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.